Replies to post #44 on Fortress Biotech Inc (FBIO)

[conix]

Dawson James started coverage on shares of Fortress Biotech
(NASDAQ:FBIO) in a report issued on Monday, The Fly reports. The brokerage set a “buy” rating on the biopharmaceutical company’s stock.

Several other equities analysts also recently weighed in on FBIO. ValuEngine upgraded shares of Fortress Biotech from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. HC Wainwright restated a “buy” rating and set a $11.00 target price on shares of Fortress Biotech in a report on Monday, May 13th. Zacks Investment Research downgraded shares of Fortress Biotech from a “buy” rating to a “hold” rating in a report on Monday, July 15th. Finally, Roth Capital assumed coverage on shares of Fortress Biotech in a report on Monday, July 1st. They set a “buy” rating and a $4.00 target price for the company. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $5.67.


FBIO stock opened at $1.58 on Monday. Fortress Biotech has a one year low of $0.49 and a one year high of $2.59. The stock has a market capitalization of $121.51 million, a PE ratio of -0.52 and a beta of 2.48. The company has a debt-to-equity ratio of 1.10, a quick ratio of 4.47 and a current ratio of 4.49. The company has a fifty day moving average of $1.45 and a 200-day moving average of $1.73.


Fortress Biotech (NASDAQ:FBIO) last announced its quarterly earnings data on Friday, August 9th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.46) by $0.22. The company had revenue of $9.25 million during the quarter, compared to analyst estimates of $7.51 million. Equities analysts forecast that Fortress Biotech will post -0.8 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Fortress Biotech by 65.8% during the second quarter. Vanguard Group Inc. now owns 2,112,586 shares of the biopharmaceutical company’s stock worth $3,169,000 after buying an additional 838,514 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Fortress Biotech by 12.8% during the fourth quarter. Geode Capital Management LLC now owns 379,972 shares of the biopharmaceutical company’s stock worth $326,000 after buying an additional 43,239 shares in the last quarter. Acadian Asset Management LLC grew its holdings in shares of Fortress Biotech by 43.1% during the second quarter. Acadian Asset Management LLC now owns 219,584 shares of the biopharmaceutical company’s stock worth $329,000 after buying an additional 66,133 shares in the last quarter. Cpwm LLC grew its holdings in shares of Fortress Biotech by 11.7% during the first quarter. Cpwm LLC now owns 191,000 shares of the biopharmaceutical company’s stock worth $340,000 after buying an additional 20,000 shares in the last quarter. Finally, Paloma Partners Management Co purchased a new stake in shares of Fortress Biotech during the second quarter worth about $246,000. Institutional investors and hedge funds own 10.02% of the company’s stock.

Fortress Biotech Company Profile

Fortress Biotech, Inc develops and commercializes pharmaceutical and biotechnology products. The company develops CNDO-109, a lysate that treats cancer-related and other conditions; tramadol HCl for managing postoperative pain; CAEL-101 for the treatment of amyloid light chain amyloidosis; and CEVA101 for severe traumatic brain injury in children and adults in the United States.